Total Payments
$83,966
2019 Payments
$4,700
Companies
3
Transactions
26
Payment Breakdown by Category
Consulting$79,250 (94.4%)
Research$4,700 (5.6%)
Food & Beverage$16.16 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $79,250 | 19 | 94.4% |
| Unspecified | $4,700 | 6 | 5.6% |
| Food and Beverage | $16.16 | 1 | 0.0% |
Payments by Type
General
$79,266
20 transactions
Research
$4,700
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $79,250 | 19 | $0 (2018) |
| Hoffmann-La Roche Limited | $4,700 | 6 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $16.16 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $4,700 | 6 | Hoffmann-La Roche Limited ($4,700) |
| 2018 | $30,210 | 7 | Merck Sharp & Dohme Corporation ($30,210) |
| 2017 | $49,056 | 13 | Merck Sharp & Dohme Corporation ($49,040) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2019 | Hoffmann-La Roche Limited | Zelboraf (Biological), COTELLIC, TECENTRIQ | — | Cash or cash equivalent | $400.00 | Research |
| Study: VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA • Category: BioOncology | ||||||
| 11/14/2019 | Hoffmann-La Roche Limited | Zelboraf (Biological), COTELLIC, TECENTRIQ | — | Cash or cash equivalent | $50.00 | Research |
| Study: VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA • Category: BioOncology | ||||||
| 09/19/2019 | Hoffmann-La Roche Limited | Zelboraf (Biological), COTELLIC, TECENTRIQ | — | Cash or cash equivalent | $150.00 | Research |
| Study: VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA • Category: BioOncology | ||||||
| 08/22/2019 | Hoffmann-La Roche Limited | COTELLIC (Drug), TECENTRIQ, Non-Covered Product | — | Cash or cash equivalent | $300.00 | Research |
| Study: A PHASE III STUDY IN COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN BRAFWT MELANOMA PATIENTS • Category: BioOncology | ||||||
| 07/18/2019 | Hoffmann-La Roche Limited | COTELLIC (Drug), TECENTRIQ, Non-Covered Product | — | Cash or cash equivalent | $2,200.00 | Research |
| Study: A PHASE III STUDY IN COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN BRAFWT MELANOMA PATIENTS • Category: BioOncology | ||||||
| 06/06/2019 | Hoffmann-La Roche Limited | Zelboraf (Biological), COTELLIC, TECENTRIQ | — | Cash or cash equivalent | $1,600.00 | Research |
| Study: VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA • Category: BioOncology | ||||||
| 03/29/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $11,500.00 | General |
| Category: ONCOLOGY | ||||||
| 03/08/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $6,200.00 | General |
| Category: ONCOLOGY | ||||||
| 03/08/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $115.00 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,150.00 | General |
| Category: ONCOLOGY | ||||||
| 01/04/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $7,200.00 | General |
| Category: ONCOLOGY | ||||||
| 01/04/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,645.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $100.00 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $13,225.00 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: ONCOLOGY | ||||||
| 10/12/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $10,800.00 | General |
| Category: ONCOLOGY | ||||||
| 09/14/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $5,700.00 | General |
| Category: ONCOLOGY | ||||||
| 08/10/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $8,300.00 | General |
| Category: ONCOLOGY | ||||||
| 07/27/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,300.00 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2017 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.16 | General |
| 06/01/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,265.00 | General |
| Category: ONCOLOGY | ||||||
| 05/18/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: ONCOLOGY | ||||||
| 05/11/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $690.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III STUDY IN COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN BRAFWT MELANOMA PATIENTS | Hoffmann-La Roche Limited | $2,500 | 2 |
| VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | Hoffmann-La Roche Limited | $2,200 | 4 |
About Dr. Mark Huberman, MD
Dr. Mark Huberman, MD is a Medical Oncology healthcare provider based in Newton, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477583441.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Huberman, MD has received a total of $83,966 in payments from pharmaceutical and medical device companies, with $4,700 received in 2019. These payments were reported across 26 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($79,250).
Ad
Practice Information
- Specialty Medical Oncology
- Location Newton, MA
- Active Since 07/04/2006
- Last Updated 08/09/2021
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1477583441
Products in Payments
- KEYTRUDA (Biological) $79,250
- COTELLIC (Drug) $2,500
- Zelboraf (Biological) $2,200
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.